CompletedNCT06235905
SPN-820 safety study in adults with depression
About this title
Read the official source — NCT06235905Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- TemeculaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: February 15, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Navitor Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06235905
- Official title
Show the full official title
An Open-Label, Single-Group Study to Evaluate the Efficacy and Safety of SPN-820 in Adults With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Temecula
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Navitor Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including NV-5138.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
